نتایج جستجو برای: prolyl dipeptidyl peptidase

تعداد نتایج: 14385  

2002
A. John Kenny Jean Ingram John Kenny

To the Editor: We wish to draw readers’ attention to the need for caution in interpreting assays of peptidases using fluorogenic substrates such as Gly-Pro-Met-2 naphthylamide (NNap). The release of the fluorophore, 2naphthylamine, may indicate the action of a tripeptidyl peptidase releasing the tripeptide, Gly-Pro-Met, but it may also result from the sequential attack of other exopeptidases, f...

Journal: :European Journal of Heart Failure 2014

Journal: :Frontiers in Physiology 2020

Journal: :Chemical communications 2016
Yi Wang Xueli Wu Yiyu Cheng Xiaoping Zhao

A novel fluorescent probe for in vitro and in vivo imaging of dipeptidyl peptidase-4 (DPP-4) was designed and synthesized. This probe is successfully utilized to screen DPP-4 inhibitors in living 3T3-L1 cells and zebrafish, which provides a novel approach for the discovery of anti-diabetes drugs.

2016
Akihiko Sato Akiomi Yoshihisa Yuki Kanno Mai Takiguchi Shunsuke Miura Takeshi Shimizu Yuichi Nakamura Hiroyuki Yamauchi Takashi Owada Takamasa Sato Satoshi Suzuki Masayoshi Oikawa Takayoshi Yamaki Koichi Sugimoto Hiroyuki Kunii Kazuhiko Nakazato Hitoshi Suzuki Shu‐ichi Saitoh Yasuchika Takeishi

BACKGROUND Heart failure (HF) and diabetes mellitus (DM) often co-exist. Treatment of DM in HF patients is challenging because some therapies for DM are contraindicated in HF. Although previous experimental studies have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors improve cardiovascular function, whether DPP-4 inhibition improves mortality of HF patients with DM remains unclear. Ther...

2018
Niranjan Kathe Anuj Shah Qayyim Said Jacob T. Painter

INTRODUCTION The risk of rheumatoid arthritis (RA) associated with dipeptidyl peptidase-4 inhibitor (DPP-4i) use is unclear. This study assesses the RA risk associated with DPP-4i use among a diabetic cohort initiating second-line therapy. METHODS This was a nested case-control study, using the adult diabetic population starting second-line antidiabetic therapy from IMS LifeLink Plus® databas...

2016
Akiko Sarashina Christian Friedrich Susanne Crowe Sanjay Patel Ulrike Graefe‐Mody Naoyuki Hayashi Yoshiharu Horie

AIMS/INTRODUCTION The efficacy and safety of drugs can vary between different races or ethnic populations because of differences in the relationship of dose to exposure, pharmacodynamic response or clinical efficacy and safety. In the present post-hoc analysis, we assessed the influence of race on the pharmacokinetics, pharmacodynamics, efficacy and safety of monotherapy with the dipeptidyl pep...

2018
Dandan Zhao Shaoqian Zhao Xiao Wang Mingbo Su Wen Liu Qinyun Ma Jie Hong Weiqiong Gu Jingya Li Ruixin Liu Guang Ning Jiqiu Wang Yifei Zhang

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1 (GLP-1) level exposure have not been reported. A trio family with a proband showing an extremely ...

2016
Xiaomei Peng Dingfeng Jiang Dongju Liu Oralee J Varnado Jay P Bae

BACKGROUND Metformin is an oral antidiabetic drug (OAD) widely used as first-line therapy in type 2 diabetes (T2D) treatments. Numerous treatment pathways after metformin failure exist. It is important to understand how treatment choices influence subsequent therapy progressions. This retrospective study compares adherence to, persistence with, and treatment progression in sulfonylurea (SU) and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید